Anti-SGCB (Beta-Sarcoglycan) Rabbit Polyclonal Antibody for WB, ELISA - Q16585

Core Product Specifications and Parameters

Biological Background: Beta-Sarcoglycan Function and Localization

• Beta-sarcoglycan (SGCB) is a 43 kDa dystrophin-associated glycoprotein also known as A3b, encoded by the SGCB gene. It is a single-pass transmembrane glycoprotein with a signal-anchor and exists in alternatively spliced isoforms.
• As a core component of the sarcoglycan complex, SGCB is part of the dystrophin-glycoprotein complex (DGC) that bridges the intracellular F-actin cytoskeleton to the extracellular matrix, critical for sarcolemma stability.
• It belongs to the sarcoglycan family, which includes alpha-, beta-, gamma-, and delta-sarcoglycans, each contributing to the integrity of the DGC in striated muscle.
• SGCB localizes predominantly to the cell membrane and sarcolemma in muscle cells, with additional cytoplasmic and cytoskeletal associations, reflecting its role in membrane-cytoskeleton linkage.
• Post-translational modifications include disulfide bonds and glycosylation, and the protein has been directly sequenced and identified by proteomics (UniProt keywords: Disulfide bond, Glycoprotein, Direct protein sequencing, Proteomics identification).
• Tissue expression is highest in cardiac and skeletal muscle, with lower levels in brain, kidney, placenta, pancreas, and lung; notably, fetal brain and fetal lung, kidney, and liver also show expression.
• Mutations in SGCB are linked to limb-girdle muscular dystrophy type 2E (LGMD2E, now LGMDR4), a severe autosomal recessive disorder causing progressive muscle degeneration.
• Additional keywords: Alternative splicing, Disease variant, Limb-girdle muscular dystrophy, Membrane, Reference proteome, Signal-anchor, Transmembrane, Transmembrane helix.

Experimental Guidance and Technical Tips

• The immunogen (aa 94-318 of human SGCB) spans the extracellular domain, which may favor detection of the mature membrane-bound form. For WB, consider using reducing conditions due to potential disulfide bonds.
• Confirm cross-reactivity in your specific sample system, as described reactivity (Human, Mouse, Rat) may require validation under your experimental conditions.
• For ELISA, consider pairing with a capture antibody targeting a distinct epitope to avoid competition.
• As a polyclonal antibody, lot-to-lot consistency can be verified using a positive control lysate from heart or skeletal muscle, where SGCB is highly expressed.
• Include appropriate controls (e.g., SGCB knockout or siRNA-treated samples) to ensure specificity, especially given the low expression in non-muscle tissues.
• Optimize antibody dilution based on your assay sensitivity; typical starting concentrations for WB range from 0.5 to 2 µg/mL, but empirical titration is recommended.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. As your sourcing partner, we offer this anti-SGCB antibody alongside validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and rare-target raw-material procurement, supporting muscular dystrophy research and diagnostic development.